Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes

NCT01693549 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT01693549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
July 20, 2017
Enrollment
84 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer